PF4 and neoplasm: PF4 then promotes downregulation of CCL5, TGFB1, SRGN and SPARC within the tumor microenvironment, immunoregulatory cells, platelets and potentially tumor cells themselves; thus, blunting the established survival benefit higher expression of these genes is associated with [31].